184 related articles for article (PubMed ID: 30953319)
1. Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Taneja A; Desrivot J; Diderichsen PM; Blanqué R; Allamasey L; Fagard L; Fieuw A; Van der Aar E; Namour F
Clin Pharmacokinet; 2019 Sep; 58(9):1175-1191. PubMed ID: 30953319
[TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial.
Maher TM; van der Aar EM; Van de Steen O; Allamassey L; Desrivot J; Dupont S; Fagard L; Ford P; Fieuw A; Wuyts W
Lancet Respir Med; 2018 Aug; 6(8):627-635. PubMed ID: 29792287
[TBL] [Abstract][Full Text] [Related]
3. Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials.
van der Aar E; Desrivot J; Dupont S; Heckmann B; Fieuw A; Stutvoet S; Fagard L; Van de Wal K; Helmer E
J Clin Pharmacol; 2019 Oct; 59(10):1366-1378. PubMed ID: 31012984
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis.
Desroy N; Housseman C; Bock X; Joncour A; Bienvenu N; Cherel L; Labeguere V; Rondet E; Peixoto C; Grassot JM; Picolet O; Annoot D; Triballeau N; Monjardet A; Wakselman E; Roncoroni V; Le Tallec S; Blanque R; Cottereaux C; Vandervoort N; Christophe T; Mollat P; Lamers M; Auberval M; Hrvacic B; Ralic J; Oste L; van der Aar E; Brys R; Heckmann B
J Med Chem; 2017 May; 60(9):3580-3590. PubMed ID: 28414242
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Autotaxin with GLPG1690 Increases the Efficacy of Radiotherapy and Chemotherapy in a Mouse Model of Breast Cancer.
Tang X; Wuest M; Benesch MGK; Dufour J; Zhao Y; Curtis JM; Monjardet A; Heckmann B; Murray D; Wuest F; Brindley DN
Mol Cancer Ther; 2020 Jan; 19(1):63-74. PubMed ID: 31548293
[TBL] [Abstract][Full Text] [Related]
7. ISABELA Studies: Plasma Exposure and Target Engagement Do Not Explain the Lack of Efficacy of Ziritaxestat in Patients with Idiopathic Pulmonary Fibrosis.
Taneja A; Jentsch G; Delage S; Randall MJ; van den Blink B; Bauer Y; Namour F
Clin Pharmacol Ther; 2024 Mar; 115(3):606-615. PubMed ID: 38071462
[TBL] [Abstract][Full Text] [Related]
8. Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis.
Tager AM
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):563-5. PubMed ID: 23125419
[No Abstract] [Full Text] [Related]
9. Pharmacokinetics and Metabolism of Ziritaxestat (GLPG1690) in Healthy Male Volunteers Following Intravenous and Oral Administration.
Helmer E; Willson A; Brearley C; Westerhof M; Delage S; Shaw I; Cooke R; Sidhu S
Clin Pharmacol Drug Dev; 2022 Feb; 11(2):246-256. PubMed ID: 34633152
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis.
Ninou I; Kaffe E; Müller S; Budd DC; Stevenson CS; Ullmer C; Aidinis V
Pulm Pharmacol Ther; 2018 Oct; 52():32-40. PubMed ID: 30201409
[TBL] [Abstract][Full Text] [Related]
12. Benzoxaboroles-Novel Autotaxin Inhibitors.
Kraljić K; Jelić D; Žiher D; Cvrtila A; Dragojević S; Sinković V; Mesić M
Molecules; 2019 Sep; 24(19):. PubMed ID: 31547058
[TBL] [Abstract][Full Text] [Related]
13. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
14. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension.
Saga H; Ohhata A; Hayashi A; Katoh M; Maeda T; Mizuno H; Takada Y; Komichi Y; Ota H; Matsumura N; Shibaya M; Sugiyama T; Nakade S; Kishikawa K
PLoS One; 2014; 9(4):e93230. PubMed ID: 24747415
[TBL] [Abstract][Full Text] [Related]
15. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
[TBL] [Abstract][Full Text] [Related]
16. Autotaxin activity increases locally following lung injury, but is not required for pulmonary lysophosphatidic acid production or fibrosis.
Black KE; Berdyshev E; Bain G; Castelino FV; Shea BS; Probst CK; Fontaine BA; Bronova I; Goulet L; Lagares D; Ahluwalia N; Knipe RS; Natarajan V; Tager AM
FASEB J; 2016 Jun; 30(6):2435-50. PubMed ID: 27006447
[TBL] [Abstract][Full Text] [Related]
17. "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.
Stylianaki EA; Magkrioti C; Ladopoulou EM; Papavasileiou KD; Lagarias P; Melagraki G; Samiotaki M; Panayotou G; Dedos SG; Afantitis A; Aidinis V; Matralis AN
Eur J Med Chem; 2023 Mar; 249():115130. PubMed ID: 36702053
[TBL] [Abstract][Full Text] [Related]
18. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
20. Experimental autotaxin inhibitors for the treatment of idiopathic pulmonary fibrosis.
Simonetti J; Ficili M; Sgalla G; Richeldi L
Expert Opin Investig Drugs; 2024 Feb; 33(2):133-143. PubMed ID: 38299617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]